Different infusion durations for preventing platinum-induced hearing loss in children with cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 8, 2016, Pages

  van As, Jorrit W ^a   van den Berg, Henk ^a   van Dalen, Elvira C ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PLATINUM; ANTINEOPLASTIC AGENT; CARBOPLATIN; OXALIPLATIN; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; CHILDHOOD CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG INFUSION; EVENT FREE SURVIVAL; HEARING IMPAIRMENT; HUMAN; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TINNITUS; TREATMENT RESPONSE; CHEMICALLY INDUCED; CHILD; DRUG ADMINISTRATION; HEARING LOSS; NEUROBLASTOMA;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; HEARING LOSS; HUMANS; NEUROBLASTOMA; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84982804501     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010885.pub3     Document Type: Review

References (35)

1. Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. Journal of Clinical Oncology 1997;15(12):3433-40.
2. Bergeron C, Dubourg L, Chastagner P, Mechinaud F, Plouvier E, Desfachelles AS, et al. Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study. Pediatric Blood & Cancer 2005;45(1):32-6.
3. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Würthwein G, et al. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatric Blood & Cancer 2006;47(2):183-93.
4. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. Journal of Pediatric Hematology/Oncology 2004;26(10):649-55.
5. Brock P, Yoeman L, Bellman S, Pritchard J. Ototoxicity in children treated with cis-platinum (CDDP) for germ cell (GCT) and other tumours. Medical and Pediatric Oncology. 1987; Vol. 15:329 (abstract 138).
6. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Medical and Pediatric Oncology 1991;19(4):295-300.
7. Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. Journal of Pediatric Hematology/Oncology 2008;30(2):130-4.
8. Eloxatin Summary of Product Characteristics. www.sanofi-aventis.co.uk/products/Eloxatin_SPC.pdf (Accessed 2 March 2010).
9. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Annals of Internal Medicine 1979;91(1):744-5.
10. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355(9209):1075-6.
11. GRADEprofiler 3.6.1. 2011.
12. Gregg RB, Wiorek LS, Arvedson JC. Pediatric audiology: a review. Pediatrics in Review 2004;25(7):224-33.
13. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics 2010;125(4):e938-50.
14. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
15. Jenney MEM. Late effects of cancer treatment and current protective measures. In: Voûte PA, Barett A, Stevens MCG, Caron HN editor(s). Cancer in Children. 5th Edition. New York: Oxford University Press, 2005:123-37.
16. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. Journal of Clinical Oncology 2005;23(34):8588-96.
17. Kremer LCM, Jellema P, Leclercq E, Noorman JK, van Dalen EC. Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2016, Issue 5. Art. No.: CHILDCA.
18. Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends in Pharmacological Sciences 2013;34(8):458-69.
19. Leahey A. A cautionary tale: dosing chemotherapy in infants with retinoblastoma. Journal of Clinical Oncology 2012;30(10):1023-4.
20. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. European Journal of Cancer 2004;40(16):2445-51.
21. McHaney VA, Thibadoux G, Hayes FA, Green AA. Hearing loss in children receiving cisplatin chemotherapy. Journal of Pediatrics 1983;102(2):314-7.
22. Meyer AK, Young NM. Auditory late effects of chemotherapy. Cancer Treatment and Research 2009;150:195-213.
23. Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. Journal of Clinical Oncology 2012;30(10):1034-41.
24. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treatment Reports 1982;66(1):19-23.
25. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
26. Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics 2009;41(12):1345-9.
27. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. Journal of Clinical Oncology 1989;7(6):754-60.
28. Skinner R. Best practice in assessing ototoxicity in children with cancer. European Journal of Cancer 2004;40(16):2352-4.
29. Van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009219.pub2]
30. Van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009219.pub3]
31. Van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/14651858.CD010181.pub2]
32. Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research 2001;7(8):2205-12.
33. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland 1979.
34. Van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD010885]
35. Van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD010885.pub2]